Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial
Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R
The American journal of clinical nutrition · 649 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2006-04-01 · Am J Clin Nutr · vol. 83 · número 4 · págs. 754–759
- Editorial
- Elsevier BV
- Citado
- 925 citas · más que el 100% de estudios similares · 23.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 32 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Heart Failure Treatment and Management · Parathyroid Disorders and Treatments
- Palabras clave
- vitamin D supplementation, vitamin D3, congestive heart failure, cytokines, inflammatory cytokines, anti-inflammatory cytokines, TNF-α, IL-10, parathyroid hormone, 25-hydroxyvitamin D, calcium supplementation, survival, inflammation
- MeSH
- humans, chronic disease, disease progression, parathyroid hormone, vitamins, vitamin d, tumor necrosis factor-alpha, interleukin-10, survival rate, double-blind method, dietary supplements, middle aged, female, male, heart failure
6 autores
- Stefanie Schulze Schleithoff🇩🇪University of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
- Armin Zittermann🇩🇪 · autor de correspondenciaUniversity of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
- Gero Tenderich🇩🇪University of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
- Heiner K. Berthold🇩🇪University of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
- Peter Stehle🇩🇪University of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
- Reiner Koerfer🇩🇪University of Bonn; Heart and Diabetes Center North Rhine-Westphalia; Arzneimittelkommission der deutschen Ärzteschaft
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Elevated circulating concentrations of proinflammatory cytokines may contribute to the pathogenesis of congestive heart failure (CHF). In vitro studies suggest that vitamin D suppresses proinflammatory cytokines and increases antiinflammatory cytokines.
Objective
We evaluated the effect of vitamin D supplementation on the survival rate and different biochemical variables in patients with CHF.
Design
One hundred twenty-three patients randomly received either 50 mug vitamin D(3)/d plus 500 mg Ca/d [D(+) group] or placebo plus 500 mg Ca/d [D(-) group] for 9 mo. Biochemical variables were assessed at baseline and after 9 mo. The survival rate was calculated for a follow-up period of 15 mo.
Results
Ninety-three patients completed the study. Significant treatment effects were observed on logarithmic-transformed serum concentrations of 25-hydroxyvitamin D (P = 0.001), parathyroid hormone (P = 0.007), tumor necrosis factor alpha (P = 0.006), and interleukin 10 (P = 0.042). 25-Hydroxyvitamin D increased by 26.8 ng/mL in the D(+) group but increased only by 3.6 ng/mL in the D(-) group. Compared with baseline, parathyroid hormone was significantly lower and the antiinflammatory cytokine interleukin 10 was significantly higher in the D(+) group after 9 mo. The proinflammatory cytokine tumor necrosis factor alpha increased in the D(-) group but remained constant in the D(+) group. The survival rate did not differ significantly between the study groups during the follow-up period.
Conclusions
Vitamin D(3) reduces the inflammatory milieu in CHF patients and might serve as a new antiinflammatory agent for the future treatment of the disease. Our data provide evidence for the involvement of an impaired vitamin D-parathyroid hormone axis in the progression of CHF.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.